Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc. (Nasdaq: DECA) is a specialty pharmaceutical company that completed a business combination with Denali Capital Acquisition Corp., a blank check company sponsored by Denali Capital that conducted its initial public offering in 2021 with a stated focus on the healthcare and life sciences sector. Semnur, whose pipeline is centered on pain management therapeutics including an epidural formulation targeting post-surgical pain, filed an 8-K with the SEC on November 20, 2023, reflecting its ongoing public-company disclosure obligations following the de-SPAC transaction. The filing was registered under accession number 0001213900-23-088773. Investors and researchers seeking complete filing histories, deal timelines, and SPAC analytics on DECA can sign up for full data access at SpacDesk.